Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Western Union Co — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Western Union Co trades at $6.05 (market cap $1.90B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 2.6× Western Union Co's market cap, and Western Union Co pays a 15.41% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Western Union Co for 96 Days on average.
| TVTX | WU | |
|---|---|---|
Market Cap | $4.88B | $1.90B |
Volume | 1,668,577 | 6,506,793 |
Sector | Health | Financials |
52-Week High | $67.52 | $10.28 |
52-Week Low | $26.79 | $5.90 |
Typical Hold Time | 0 Days | 96 Days |
Enterprise Value | $5.01B | $1.81B |
Dividend Yield | — | 15.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Western Union (WU) trades at $6.05, down 0.98% on the day and near its 52-week low of $6.00. The stock shows bearish technical signals with recent earnings misses in Q1 and Q2 2026. Fundamentally, WU maintains strong profitability with a 9.79% net margin and attractive valuation metrics including a P/E of 4.92. The company's $200 million cost-cutting initiative and Intermex acquisition aim to drive future growth despite revenue declines from $4.5B in 2022 to $4.05B in 2025.
WU presents a value opportunity with deep undervaluation but faces execution risks. The stock trades below analyst consensus target of $6.71, offering 11% upside potential. However, declining revenue trends, integration challenges from the Intermex acquisition, and competitive pressures in money transfer services create headwinds. Investor sentiment remains cautious with only 12% buy ratings from analysts, reflecting concerns about the company's digital transition and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
